Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOV-3001 and Lifileucel in Advanced Melanoma
NCT06940739Phase 2Recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- Mar 2025
- Primary completion
- Jun 2032
- Modality
- Prophylactic Vaccines, Immunomodulatory ADCs, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of IOV-3001 in melanoma, sponsored by Iovance Biotherapeutics. Primary endpoints: Safety and Tolerability at 30 days and Recommended Dose for Phase 2 at 30 days. Started Mar 2025; status: recruiting.
02
Drugs
IOV-3001
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06940739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940739.